Physicians treating Alzheimer's patients discussed to prescribe lecanemab (Leqembi). (Reuters)
Researchers reviewed the in multiple sclerosis (MS), Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, stroke and cerebrovascular disease, traumatic brain injury, and Parkinson's disease. (Nature Reviews Neurology)
Mobile and helped monitor MS disability and fatigue and distinguished patients from healthy controls. (NPJ Digital Medicine)
(Ocrevus) showed results consistent with IV infusion at 48 weeks in MS, Roche said.
The NeuroRights Foundation called for to safeguard brain data in the consumer neurotechnology market.
A small study suggested preoperative cognitive training may reduce incidence in people undergoing coronary artery bypass grafting. (JAMA Network Open)
An exploratory analysis of phase II data suggested that , a monoclonal antibody that binds aggregated alpha-synuclein, slowed motor progression in rapidly progressing early-stage Parkinson's disease. (Nature Medicine)
People who had during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia when they were over 70. (Neurology)
The investigational antisense oligonucleotide GTX-102 showed clinical benefit in a phase I/II study of , Ultragenyx announced.
Based on phase II trial data, Sage Therapeutics for mild cognitive impairment in Parkinson's disease.
Meanwhile, improved motor outcomes for Parkinson's patients in a phase III study, Cerevel Therapeutics said.
Oral atogepant (Qulipta) became the blocker recommended by health authorities in England for chronic and episodic migraine prevention.